CTRI, ICMR-National Institute of Medical Statistics, New Delhi, India.
Indian J Pharmacol. 2020 Jul-Aug;52(4):272-282. doi: 10.4103/ijp.IJP_24_20.
To present a descriptive analysis of the clinical studies registered in the Clinical Trials Registry - India (CTRI) and deduce its impact.
We searched the CTRI databease for all registered clinical studies from July 20, 2007 to May 31, 2018. Extracted data were analyzed in three time periods i.e., Periods 1, 2, and 3 based on the major activities and milestones of the CTRI. In addition, comparative registrations of the various Primary Registries of the WHO were compiled and registration policy of Indian journals with regard to trial registration assessed.
A total of 20,160 clinical studies were submitted to the CTRI in the designated study period. Of the registered 14,341 clinical studies, 10,485 (76.3%) were interventional trials which were either regulatory (n = 2004), academic non-regulatory (n = 3855), or those conducted as part of PG thesis (n = 4626) trials. Regulatory trials registration numbers varied according to the Indian regulatory scenario. PG thesis trial registrations showed a steep rise, although unlike regulatory trials, these were mostly retrospective registrations. CTRI registration numbers were comparable to that in other Primary Registries. Instructions to authors of 48% indexed Indian journals made a mention of trial registration.
The CTRI has a strong global presence and has enhanced the transparency of regulatory trials as well as academic research particularly thesis-based work. The latter is expected to help improve standard of research and prevent repetitive research. Additional support from Indian journal editors by strict implementation of prospective registration is crucial for increasing compliance by researchers.
对在临床试验注册印度中心(CTRI)注册的临床研究进行描述性分析,并推断其影响。
我们从 2007 年 7 月 20 日至 2018 年 5 月 31 日在 CTRI 数据库中搜索所有已注册的临床研究。根据 CTRI 的主要活动和里程碑,将提取的数据分为三个时间段(第 1 期、第 2 期和第 3 期)进行分析。此外,还编译了世界卫生组织各主要登记处的比较登记情况,并评估了印度期刊的试验登记政策。
在指定的研究期间,共有 20160 项临床研究提交给 CTRI。在已注册的 14341 项临床研究中,有 10485 项(76.3%)为干预性试验,其中 2004 项为监管试验,3855 项为学术非监管试验,4626 项为 PG 论文试验。监管试验的注册数量根据印度监管情况而有所不同。PG 论文试验的注册数量呈上升趋势,尽管与监管试验不同,这些试验大多是回顾性注册。CTRI 的注册数量与其他主要登记处相当。48%的索引印度期刊的作者指南都提到了试验注册。
CTRI 在全球范围内具有强大的影响力,不仅提高了监管试验的透明度,还提高了学术研究,特别是基于论文的工作的透明度。后者有望帮助提高研究水平,防止重复研究。印度期刊编辑通过严格执行前瞻性注册来提供额外支持,对于提高研究人员的合规性至关重要。